Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients

• Status: Recruiting
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is up to 6 hours. The liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. Typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. Therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• patients who are undergoing a laparoscopic sleeve gastrectomy for severe obesity who are between 13 and 2018 years of age.

• Only patients treated at the Children's Hospital of Richmond at VCU will be included.

Exclusion Criteria:

• patients less than 13 or greater than 2018 years of age

• patients with an allergy to bupivacaine

• any patients undergoing any additional procedures at the time of the laparoscopic sleeve gastrectomy.

• English or Spanish proficiency will be necessary.